Key facts
- This page summarizes Dipal Doshi's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jul 2022, 16:03.
Dipal Doshi - 27 Jul 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- TRDA
- Reported as of
- 27 Jul 2022
- Net transaction value
- -$24,000
- SEC form
- 4
- Accepted by SEC
- 29 Jul 2022, 16:03:33 UTC
- Prior SEC filing
- 06 Jul 2022
- Next SEC filing
- 31 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jared Cohen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dipal Doshi filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 29 Jul 2022.
Change
- Previous filing in this sequence was filed on 06 Jul 2022.
- Current net transaction value: -$24,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRDA
transaction
Common Stock
Sale
- Transaction value
- $24,000
- Shares
- -2,000
- Change %
- -0.95%
- Price
- $12.00
- Shares after
- 208,710
- Date
- 27 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.